Le Lézard
Classified in: Science and technology
Subject: PLW

Roqos Gets Patent For Game-changing VPN Technology, OmniVPNtm


TYSONS, Va., March 7, 2022 /PRNewswire-PRWeb/ -- Roqos, the innovative leader of cybersecurity and VPN solutions, has announced that OmniVPN which is the only VPN technology that allows connections over any network access including CGNAT, multiple NATs, connections with private IP addresses, and cellular connections is now patented. With the help of OmniVPN, complex network settings needed for VPN connections such as port-forwarding and UPnP which are considered as cybersecurity risks have been eliminated.

"Our Click&Connect VPN technology OmniVPN will change the enterprise VPN space with its capability of limitless connectivity." said Sezen Uysal, founder and CEO of Roqos. "We are very excited about our OmniVPN, as it is the foundation for our upcoming Security Service Edge (SSE) solution with Zero Trust".

Roqos OmniVPN is available on all Roqos Core appliances and Roqos VPN apps for phones and laptops. For more information on OmniVPN please visit https://www.roqos.com/vpn.html

About Roqos
Founded in 2013, Roqos, Inc., based in Tysons, VA, provides cybersecurity and VPN solutions via its high performance appliances, Roqos Cores, which are cloud-managed and equipped with automatic software and security updates, as well as real-time alerting. For more information, visit Roqos website roqos.com, or Linkedin page https://www.linkedin.com/company/roqos-inc- .

Media Contact

Roqos Marketing, Roqos, Inc., 1 571-323-1500, [email protected]

 

SOURCE Roqos, Inc.


These press releases may also interest you

at 07:05
GlycoMimetics, Inc. , today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you...

at 07:05
Harrow , a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first...

at 07:05
Mind Medicine (MindMed) Inc. , (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study...

at 07:05
Enterprises in France, seeking better returns on investment, are turning to service providers that can manage their Salesforce platforms more efficiently, according to a new research report published today by Information Services Group (ISG) , a...

at 07:05
Mission Bio, a leader in single-cell multiomic solutions for precision medicine, today announced the launch of a new single-cell capability that enhances our understanding of translocations (chromosomal rearrangements) in gene-edited therapies....

at 07:05
Aldeyra Therapeutics, Inc. (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the...



News published on and distributed by: